Category: In the News

Announcing our newest location in the Pacific Northwest

We are thrilled to officially announce our newest clinic location near Portland, Oregon in the Pacific Northwest!

Dr. Shannel Adams and Dr. Angeline Beltsos

Vios is led by Chief Medical Officer/CEO Dr. Angie Beltsos, who is board certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility (REI), practicing medicine since 1991. The new location will feature Shannel R. Adams, MD, FACOG, at the helm – a Portland native and double board-certified OB/GYN and reproductive endocrinologist.

“We are thrilled to have Dr. Adams leading our Pacific Northwest office,” explains Dr. Beltsos. “Her extensive knowledge and dedication to helping people build families is completely aligned with our Vios core values of vision, innovation, teamwork, and passion. Together, we look forward to leading the way toward expanded innovative and patient-centric fertility care options in the Pacific Northwest.”

Highly skilled in all areas of reproductive health, Dr. Adams has a particular expertise and interest in, fertility preservation, male fertility, third party reproduction, and holistic care of both mind and body. She received her undergraduate degree focusing on ethics from Duke University and went on to medical school at Oregon Health and Science University where she graduated in June 2010. Dr. Adams has been recognized with many awards for her contributions to the fields of medicine, reproductive endocrinology, and family planning and has presented numerous times on the topics of Oncofertility, fertility preservation, chromosome screening technologies, and infertility.  She credits her close-knit family and strong female role models with inspiring her to choose medicine as a profession and reproductive endocrinology as her specialty. Taking care of women and playing a trusted role in their healthcare is her passion. She considers it an honor to have an intimate role in the lives of her patients as they build their family or empower themselves with preservation options.

“I’m excited to join the Vios team to help expand our unique approach to fertility care services to the Pacific Northwest,” explains Dr. Adams. “I have the best of both worlds -to be in a community I love while also being able to bring new innovations and cutting-edge technology to offer a greater chance of success for my patients.”

Vios provides patients with innovative, cutting-edge fertility treatment options to meet the diverse needs of their family planning goals. As a team, they strive to be open-minded and forward thinking when evaluating new data, research and technologies that have the potential to improve the care and results they provide to patients.

Vios Fertility Institute – Pacific Northwest is located at 2501 NE 134th Street, Suite 100, Vancouver, Washington 98686.  For more information or to make an appointment, please call 866.955.0766 or complete our online form here.

Read the full press release.

Study finds COVID-19 does not cause female sterility

Protecting your health, and the health of your future family is important. Choices like vitamins and body weight can impact your goal to have a family. A new choice for women is whether they should receive the COVID-19 vaccine but a recent study has found the vaccine does not cause female sterility.

The study, published in ASRM’s Fertility & Sterility F&S Reports, showed no effect on a woman’s implantation rates or sustained implantation rates. This study which used frozen embryos of women who had the virus, vaccine, and neither showed no difference in rates from the three groups.

If you decide to move forward with getting vaccinated which vaccine should you get? According to American College of Obstetricians and Gynecologists (ACOG), all three vaccines are reasonable choices for patients undergoing a fertility journey or are pregnant. ACOG recommends the vaccine for women who are trying to get pregnant as well as already pregnant.

Getting the vaccine is your choice. Some information to remember is unvaccinated pregnant women have an increased risk of severe symptoms from COVID-19. If you get the virus while pregnant, your chances of needing intensive care and a ventilator are increased putting your unborn child at higher risk of preterm birth.

Vios is proud to support University of California – San Francisco’s ASPIRE study that seeks to assess the safety of pregnancy during the COVID-19 pandemic. We encourage our pregnant patients to enroll and contribute to this important research.

If you have questions about the COVID-19 vaccine contact a provider or learn more here.

Family Building for LGBTQIA+

June marks the beginning of Pride Month, commemorating the Stonewall Riots and celebrating the LGBTQIA+ community. June 1 also is #LGBTQFamiliesDay, created for individuals, families, and allies to celebrate and support LGBTQIA+ families. Family comes in many forms and everyone’s path to their family is unique to their journey. No matter what your journey is, anyone who struggles to build a family should have the opportunity including the LGTBQIA+ community. According to Resolve, between 2 million and 3.7 million children under the age of 18 have a LGTBQIA+ parent.

For most LGTBQIA+ single people and couples, the journey to building your dream family can have a different path than what may be considered “traditional”. At Vios, we are far from “traditional” ourselves and are an ally for the LGTBQIA+ community, here to help those wishing to become parents.

Recently, in the state of Illinois a bill was passed changing the definition of infertility providing insurance coverage to the LGBTQIA+ community. HB3709 amends the IL Insurance Code to provide coverage for the diagnosis and treatment of infertility shall be provided without discrimination on the basis of age, ancestry, color, disability, domestic partner status, gender, gender expression, gender identity, genetic information, marital status, national origin, race, religion, Sex, or sexual orientation. It removes provisions stating that “infertility” means the inability to conceive after one year of unprotected sexual intercourse or the inability to sustain a successful pregnancy. You can read more about this bill here.

There are three necessary components to make a baby: eggs, sperm, and a uterus. Thanks to improved medicine and technology, as well as generosity from third-party donors, same sex couples and single individuals have more options than ever to build the family of their dreams. From sperm donation and IUI, InVoCell for reciprocal IVF, egg donation, and gestational carrier Vios Fertility Institute can help bring the pieces together for all our patients. LGBTQ+ individuals and couples do not necessarily have a diagnosis of infertility so pregnancy rates per cycle are generally high in these cases.

If you need help financing your treatments learn more about our financing partners here!

We Welcome Center for Reproductive Health and Dr. Scott Springer to Our Team

Vios Fertility Institute Physicians, Dr. Springer, Dr. Jeelani, Dr. Beltsos, and Dr. Louden.

We are proud to officially announce the acquisition of Center for Reproductive Health, a widely-respected fertility practice founded by Dr. Scott Springer with locations in Crest Hill, IL and Geneva, IL. Read our full press release here.

A board-certified physician who specializes in Reproductive Endocrinology and Infertility, Springer became disenchanted early in his career with the standard practice business model that had nurses and technicians doing most of the work.  While still early in his career, Springer desired a better way to serve and care for his patients, so in 2001 he introduced the Center for Reproductive Health with a commitment to providing fertility treatments in a one on one personalized patient setting.

Vios is led by CEO and Chief Medical Officer Dr. Angeline Beltsos, who is board certified in Obstetrics and Gynecology and in Reproductive Endocrinology and Infertility (REI), practicing medicine since 1991.  Dr. Beltsos, along with Vios physicians including Dr. Roohi Jeelani and Dr. Erica Louden, will join Dr. Springer in serving patients at the Crest Hill and Geneva locations.

“We are honored to have Dr. Springer join the team and bring his incredible reputation, passion and expertise for building families to Vios,” explains Dr. Beltsos.  “We are excited to partner with him to increase our services and access to fertility care to the Western and Southwest suburbs of Chicago.”

Vios Fertility Institute now has 11 locations in the Chicagoland, Milwaukee, and St. Louis regions and accepts a wide range of insurance options. To schedule an appointment, click here.

Environment, Nutrients and Affects on Fertility: Dr. Amber Cooper Discusses

Age is an important factor in a woman’s ability to get pregnant, but lifestyle may also play a vital role.

Currently, research shows that certain chemicals in our environment could have negative effects on fertility but questions still remain on exactly what harms fertility, how much exposure is dangerous, or when the exposure is dangerous.

Types of chemicals in the environment which have the ability to affect fertility are called Endocrine Disrupting Chemicals (EDCs). These chemicals can be found in food, water, plastics, detergents and more. Once ingested, some of these chemicals may disrupt egg quality or quantity, decrease sperm count, or cause early menopause.

Dr. Amber Cooper, a Vios physician in our St. Louis region, spoke with FOX2 in St. Louis about how environment and nutrition affect fertility. Watch for more information about which chemicals to avoid and lifestyle changes that can help.

After the interview, Dr. Cooper answered patient questions on the topic during a Facebook Live.

Patient FAQs: Egg and embryo storage in the TMRW platform

Vios Fertility Institute is proud to be the first fertility clinic in the world to offer the TMRW Platform to patients. The TMRW platform is the first and only automated technology platform that safely stores, manages, and identifies frozen eggs and embryos. (Read the official press release here.)

What does this mean for Vios patients? See some Frequently Asked Questions and their answers below:

What is the TMRW Platform?

Essentially, it is a high-tech embryo or egg storage tank. Typically, embryos and eggs are frozen and then stored in protective, highly sophisticated, tanks. The TMRW platform is all of this PLUS cutting-edge software – a platform – that continuously monitors and provides 1000s of data points every day to provide real time information about the precious cells stored within. This is the first and only automated platform for the management, identification, and storage of the frozen eggs and embryos used in IVF.

When will eggs or embryos first be stored in the TMRW platform?

The first embryos were moved into the TMRW platform in January, 2021. Patients who have embryos or eggs stored at Vios Fertility Institute through our Chicago IVF Lab will have their tissue placed in the TMRW platform from that point forward and we are transferring our existing inventory of eggs & embryos into the TMRW platform. We expect the TMRW platform to be available in our St. Louis region sometime in 2021.

If I want to move my existing stored embryos or eggs to the TMRW platform, how do I do this?

We are in the process of transferring ALL currently stored eggs & embryos at Vios Fertility Institute Chicago IVF Lab into the TMRW platform. There is no action needed from you, as a patient, to make this happen. We are as excited as you are! If you’d like to talk with your doctor about this, please call and make an appointment.

Does this mean my embryos or eggs aren’t safe where they are currently?

Your embryos and eggs have always been safe. Now, they will be even safer.

Vios has also always upheld the highest levels of safety and security for eggs and embryos stored with us. With the TMRW platform, we have an opportunity to utilize cutting-edge technology to continue to deliver on this promise and provide enhanced monitoring. We are proud to offer it to our patients.

TMRW has created the first and only automated platform for the management, identification, and storage of the frozen eggs and embryos used in IVF.

This does not mean, however, that the current storage system is subpar or ineffective. The standard storage system has been in place – safely – at clinics around the world, including Vios, for many years now. Any tissue stored in these tanks can be assumed to be safe.

The current practices used, however, are manual and labor intensive.

TMRW’s technology automates and digitizes the entire process, which helps reduce the risk for human error and more importantly, allows the clinic to individually track eggs and embryos 24/7 through remote monitoring, sensors and state of the art software.

This technology essentially digitizes an existing system and brings clinics up to speed with the rest of the medical field.

Will use of the TMRW platform increase my frozen egg or embryo storage cost?

The installation of the TMRW platform will not be the cause of a storage price increase.

Over time, storage costs may increase as standard operating costs increase. Information about storage cost is available and you always can discuss this with your healthcare team.

Vios Fertility Institute Patients Are First to Have Embryos Transferred to TMRW

As Egg Freezing and IVF Rates Hit New Highs, Vios Fertility Institute Goes LIVE with TMRW, the World’s First Technology Platform that Stores, Manages, and Identifies Frozen Eggs and Embryos

Chicago Couple is First to Have Embryos Transferred

 

CHICAGO, IL (February 3, 2021) – By the year 2100, approximately 300 million people will be born from in vitro fertilization (IVF), something that seemed impossible until the birth of Louise Brown in 1978. TMRW Life Sciences (“TMRW”) is determined to assist in those future births by effectively managing all frozen fertility specimens with the first and only automated technology platform that safely stores, manages and identifies frozen eggs and embryos. Today, Vios Fertility Institute – Chicago announces it is the first clinic to go live and begin storing patient specimens.

TMRW technology platform at Vios“No one undertaking IVF should ever have to worry about the safety of their embryos and eggs,” said Joshua Abram, Founder and Co-CEO of TMRW. “Three hundred million babies are expected to be born via IVF globally by 2100. With TMRW we have brought the safe storage and management of life’s most precious cells into the 21st Century.”

TMRW is the solution to a wide range of issues that have plagued fertility clinics through the years such as embryo mix-ups, incorrect transfers of embryos and catastrophic failures that resulted in the loss of thousands of irreplaceable eggs and embryos. While current methods are manual and labor intensive, they have remained unchanged since the advent of IVF. TMRW’s technology automates and digitizes the entire process, which helps reduce the risk for human error and more importantly, allows the clinic to individually track eggs and embryos 24/7 through remote monitoring, sensors and state of the art software.

Additionally, TMRW’s automated solution improves IVF by replacing the current archaic system of storage — which is not equipped to handle the soon to be hundreds of millions of fertility specimens — with a cryo-robot featuring secure, reliable technology that dramatically reduces risk and provides peace of mind.

“As we see a substantial increase in patients seeking IVF and in egg freezing – up 41% percent and 31.5% over the previous year – I am thrilled that Vios is the first fertility clinic in the world that offers TMRW to its patients,” explains Dr. Angie Beltsos, CEO & Chief Medical Officer of Vios Fertility Clinic. “IVF patients and those wanting to preserve their fertility deserve the most sophisticated care available, and there is nothing more powerful than combining our top-notch embryology services with TMRW’s game-changing technology. The peace of mind the TMRW platform offers extends to doctors, embryologists and patients alike.”

Chicago couple, Mayrav Dolgin and Renee Genova, have received fertility treatments at Vios Fertility Clinic resulting in two beautiful sons -Jonah age 2 and Elan 6 mos. They are the first patients of Vios to have their remaining embryos stored using TMRW’s new platform.

“The fertility journey can be difficult enough without having to worry about the safety of your embryos,” explains Dolgin. “Mayrav and I were ecstatic to learn that our precious embryos would be the first to be stored in the TMRW cryo-robot,” adds Genova. “Knowing that our remaining embryos will be cared for and looked after with the most advanced technology available gives us tremendous reassurance that our ability to continue building our family in the future is protected.”

The TMRW platform’s key proprietary features include:

  • A 24/7 state-of-the-art, cloud-based monitoring system that makes thousands of wellness checks on stored samples every day. TMRW’s onsite and remote communication system uses predictive analytics to proactively identify and address any safety or storage trends before they become issues.
  • Each patient is assigned an RFID tag with a unique identifier, enabling clinics to identify and track every fertility cell, dramatically reducing the possibility of mislabeled or missing samples.
  • An encrypted, HIPAA-compliant software system, providing the highest level of data privacy and security available.
  • Proprietary labware with thermal properties and proven storage freezer provides the ability to maintain safe cryogenic temperatures to safeguard eggs and embryos even without electrical power or human intervention for more than two weeks, in case of severe emergencies such as natural disasters.

Towards the end of the year, TMRW plans to launch an app that will allow patients to track their frozen specimens using a smartphone. By the end of 2021, TMRW’s platform will be used in leading fertility clinics comprising more than 30% of all IVF cycles in the U.S. The company hopes to expand into UK-based fertility clinics in summer of 2021.

About Vios Fertility:
Established in 2015, Vios Fertility Institute is one of the fastest growing fertility clinics in the U.S. with 11 locations in the Chicago, Milwaukee and St. Louis regions. Woman owned, the Vios mission is to help patients find their way to fertility health with the highest chances of success. Vios offers innovative, scientific, and cutting-edge treatment options along with an unparalleled patient experience. www.ViosFertility.com

About TMRW Life Sciences:
TMRW has created the world’s first automated platform designed specifically for cryo-management of eggs and embryos used in IVF. TMRW’s RFID-enabled, complete digital chain of custody SaaS technology radically improves on the error-prone manual and analog methods that have gone unchanged throughout the history of IVF, significantly reducing the chances of implantation mix-ups or loss of eggs and embryos. The TMRW team includes many of the world’s most celebrated innovators in fertility, embryology, cryo-management, automation, software development and robotics to name a few of the disciplines involved. TMRW’s co-founders, Joshua Abram, Alan Murray, and Dr. Jeffrey Port, are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion. To date, TMRW has raised $50 million. For more information, please visit TMRW.org.

 

COVID-19 Vaccine and Fertility: What You Need To Know

Graphic of COVID-19 Vaccine and Fertility, What You Need to KnowLately, we hear many questions from patients about the COVID-19 vaccine and fertility and impact on pregnancy.

Vios Fertility Institute follows the guidelines from both the American Society for Reproductive Medicine (ASRM) and The American College of Obstetricians and Gynecologists (ACOG) in recommending that pregnant women, and women seeking to become pregnant, get the vaccine as it becomes available. These guidelines are constantly adjusted as new data is available and our team will continue to stay on top of the changes.

What else do you need to know about the COVID-19 vaccine and its impact on fertility?

  • Both the Pfizer and Moderna vaccines are messenger ribonucleic acid (mRNA)-based and therefore do not contain the live virus. This means that the vaccine elicits an immune response so if the recipient were to get COVID-19 she would have some immunity over it.
  • The vaccine does NOT appear to interfere with fertility in men or women.

Dr. MacKenzie Purdy and Dr. Roohi Jeelani answered many questions on this topic during our Instagram Live this week. Click below to watch!

 

View this post on Instagram

 

A post shared by Vios Fertility (@viosfertility)

ASPIRE Study: COVID19 and Pregnancy

Vios Fertility Institute is proud to partner with the University of California-San Francisco to make patients aware of the ASPIRE study regarding COVID19 and pregnancy. ASPIRE stands for Assessing Safety of Pregnancy In the Coronavirus Pandemic.

ASPIRE study on COVID19 and pregnancy

ASPIRE is a nationwide prospective cohort study of pregnant women and their offspring during the COVID-19 pandemic. All Society for Assisted Reproductive Technology (SART) member clinics have been invited to share this study information with their pregnant patients, directing patients to register to participate at this website.

From ASPIRE, “The goal of this study is to help understand the spread of COVID-19 infection among pregnant women and how infection might affect the health and wellbeing of pregnant mothers and their babies, particularly when the infection occurs in early pregnancy or without any symptoms. The goal is for this knowledge to inform and empower pregnant women and their healthcare providers to provide the best possible care for their pregnancies and future babies. Also, women and couples planning pregnancies will gain important information to help make decisions for their families.”

ASPIRE is focused on the first trimester, a critical and vulnerable period when all of a baby’s organ systems form and the placenta – the crucial connection between mom and baby – develops.

Currently, there are no data about the effects of COVID19 infections in the first trimester. The ASPIRE study will provide critical information to:

(1) Guide the care of pregnant women
(2) Protect the safety of their babies and families
(3) Help those considering pregnancy in the future understand what it means to be pregnant in this new era

Becoming pregnant at any time is a personal choice and with the added uncertainty of a global pandemic, we realize this decision did not come lightly. We celebrate your pregnancy!

We’re also careful to counsel our patients at every step of their care journey about COVID19 and pregnancy considerations and safety guidelines so that you can feel informed and an active and empowered partner in your care.

Who can join the ASPIRE Study?
Anyone who is over the age of 18 and is between 4 – 10 weeks pregnant. Eligible participants will be compensated financially.

  1. You’ll be asked to:
    1. Submit frequent, quick (<1 minute each) symptom tracking reports using your mobile phone and/or computer.
  2. 2. Collect finger-stick blood samples from home at several points throughout your pregnancy. (A helpful how to video is here.)
  3. 3. Give permission to review medical records related to your pregnancy, delivery and baby’s development.
  4. 4. Complete questionnaires online about your health during your pregnancy and after delivery of your baby.

How to get started:

Visit https://aspire.ucsf.edu/ to learn more and register on their website here.

Do you have additional questions about COVID-19 and fertility treatment at Vios? Click here for our latest update.

Miscarriage Treatment Options: Dr. MacKenzie Purdy Answers Your Questions

Miscarriage is a heartbreaking reality for many as they try to conceive and, sometimes, a woman can experience multiple miscarriages in a row.

Recurrent Pregnancy Loss (RPL) is defined by the American Society for Reproductive Medicine (ASRM) as two or more consecutive pregnancy losses. We know this is a heartbreaking loss and we are committed to helping our patients find answers and treatment options to help.

The first step is a series of diagnostic tests to understand what may be causing the miscarriages. There are some common causes of RPL including genetic, hormone imbalance, uterine abnormality, and undiagnosed medical conditions. Some reasons remain unknown despite the myriad of available testing options.

Dr. MacKenzie Purdy, a Vios physician in our St. Louis region, spoke with FOX2 in St. Louis about miscarriage and recurrent pregnancy loss. Watch for more information about diagnosis and testing as well as various treatment options for RPL.

After the interview, Dr. Purdy answered patient questions on the topic during a Facebook Live.